ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. STAR-TREC and TESAR trials: strengthenin…

STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer

The Lancet Oncology·August 23
OncologyPractice changingRectal CancerClinical Trial (Randomized)ChemoradiotherapyOrgan Preservation / Non-Operative ManagementRadiotherapyAdult

Summary

View source

What was studied

This paper reports on the STAR-TREC and TESAR trials, which investigate organ preservation (non-operative management) as an alternative to total mesorectal excision (TME) surgery in rectal cancer patients who achieve a clinical complete or near-complete response to (chemo)radiotherapy.

Study limitations

The full text of the paper was not available for extraction of specific numerical results, response rates, or detailed outcome data; key findings and limitations cannot be confirmed from the provided metadata alone.

Clinical implications

Clinicians managing rectal cancer should follow the STAR-TREC and TESAR trial results closely, as they are designed to provide high-level evidence for or against organ preservation strategies as standard-of-care alternatives to TME.

Related Questions

Explore related topics

What is the evidence for watch-and-wait organ preservation after chemoradiotherapy in rectal cancer?How does non-operative management compare to total mesorectal excision in rectal cancer patients with complete clinical response?What are the recurrence rates and quality of life outcomes with organ preservation strategies in rectal cancer?

Publication Details

Year
2026
Journal
The Lancet Oncology
Source
View article
Keep scrolling
More content below.
Up Next